RxDoctor Payments Data

Sherie O'Connell

Physician Assistant · Albany, NYNPI 1235448549

Payments from drug & device makers

$4,897in general payments, 2019–2025

Across 260 payments — averaging $18.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$950
  • Lilly USA, LLC$447
  • Amgen$269
  • AstraZeneca$248
  • Pfizer$238
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$4,897100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,897 in reported general payments places this provider in the 90th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$10,596
Medicare patients
58
Services billed
181

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide35$44,261
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$21,818
XareltoRivaroxaban19$17,587
FarxigaDapagliflozin Propanediol11$5,993
Albuterol Sulfate HfaAlbuterol Sulfate39$1,652
Gabapentin99$1,253
Vilazodone Hcl11$1,228
Bupropion XlBupropion Hcl44$1,171
SynthroidLevothyroxine Sodium12$1,157
Omeprazole78$1,041
Duloxetine Hcl46$965
Carbidopa-LevodopaCarbidopa/Levodopa15$947
Levothyroxine Sodium76$808
Olanzapine11$742
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen59$725

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$950$44,26135 claims
GSKTrelegy Ellipta$89$21,81835 claims
AstraZenecaFarxiga$248$5,99311 claims
AbbVieSynthroid$1,524$1,15712 claims
Lilly USA, LLCOlanzapine$447$74211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Albany

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →